Test-Retest Reliability of Patient Global Assessment and Physician Global Assessment in Rheumatoid Arthritis
ABSTRACT As a guide to treatment of rheumatoid arthritis (RA), physicians use measurement tools to quantify disease activity. The Patient Global Assessment (PGA) asks a patient to rate on a scale how they feel overall. The Physician Global Assessment (MDGA) is a similar item completed by the assessing physician. Both these measures are frequently incorporated into other indices. We studied reliability characteristics for global assessments and compared test-retest reliability of both the PGA and the MDGA, as well as other commonly used measures in RA.
We studied 122 patients with RA age 17 years or older. Patients who received steroid injection or change in steroid dose at the visit were excluded. Patients completed the HAQ, PGA, visual analog scale for pain (VAS Pain), VAS Fatigue, and VAS Sleep. After seeing their physician, they received another questionnaire to complete within 2 days at the same time of day as clinic visit. Physicians completed the MDGA at the time of the patient's appointment and at the end of their clinic day. Test-retest results were assessed using intraclass correlations (ICC). "Substantial" reliability is between 0.61-0.80 and "almost perfect" > 0.80.
Four rheumatologists and 146 patients participated, with 122 questionnaires returned (response rate 83.6%). Test-retest reliability was 0.702 for PGA, 0.961 for MDGA, and 0.897 for HAQ; VAS results were 0.742 for Pain, 0.741 for Fatigue, and 0.800 for Sleep. The correlation between PGA and MDGA was -0.172.
PGA, MDGA, HAQ, and VAS Pain, VAS Fatigue, and VAS Sleep all showed good to excellent test-retest reliability in RA. MDGA was more reliable than PGA. The correlation between PGA and MDGA was poor.
- SourceAvailable from: Jean-Louis Thonnard[Show abstract] [Hide abstract]
ABSTRACT: ABILHAND is a Rasch-built questionnaire that measures manual ability in rheumatoid arthritis (RA) patients. This study aimed to examine the test-retest reliability and the responsiveness of ABILHAND in RA patients. Eighty-eight patients underwent 3 evaluations: the first evaluation was at baseline (time 1), the second was 2 weeks later (time 2), and the third was 1 year later (time 3). Disease activity was assessed using the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP). Patients rated the intensity of their RA-related pain using a 100-mm visual analog scale for pain and completed questionnaires based on their activity limitations (ABILHAND and the Health Assessment Questionnaire) and quality of life. The responsiveness analyses were conducted by using global, group, and individual approaches. The global approach showed significant differences between the time 1 and time 3 scores of the DAS28-CRP (P = 0.04) and ABILHAND (P = 0.04). Based on the changes in disease activity scores and the European League Against Rheumatism response criteria, the sample was divided into 3 groups: deteriorated, stable, and improved. The mean ± SD changes in manual ability were higher in the deteriorated (-1.23 ± 1.53 logit) and in the improved (1.22 ± 2.06 logits) groups than in the stable group (0.48 ± 1.09 logit). The effect size and standardized response mean confirmed that observation. The minimal clinically important difference was assessed in each group of patients. The ABILHAND questionnaire exhibited responsiveness in detecting slight changes in RA patients. Therefore, the ABILHAND tool can be used to evaluate the functional status of RA patients in clinical trials and settings.01/2011; 63(1):135-41. DOI:10.1002/acr.20346
- [Show abstract] [Hide abstract]
ABSTRACT: Self-assessments of health are a strong predictor of mortality. Whether self-assessment of health provides additional information beyond a physician's assessment is unclear. We analyzed data on 14,530 US adults from the Third National Health and Nutrition Examination Survey. General self-rated health (GSRH)-"In general, would you say your health is Excellent, Very Good, Good, Fair, or Poor?"-and a single question to physician examiners following a medical examination rating participants' health, both on a 5-point scale of Excellent, Very Good, Good, Fair, or Poor were assessed for the period 1988-1994. All-cause mortality was assessed through December 31, 2006 (n = 3,460 deaths). Agreement between participant GSRH and physician-assessed health was 53.8% (42.1% Excellent/Very Good, 8.7% Good, and 3.0% Fair/Poor; weighted Kappa statistic = 0.20). After adjustment, participants who reported better GSRH compared to the physician assessment of their health experienced lower mortality (hazard ratio = 0.76, 95% CI: 0.66-0.87). Also, participants reporting worse health than the physician assessment experienced higher mortality (hazard ratio = 1.45, 95% CI 1.24-1.70). Individuals who reported worse health than was assessed by a physician had increased mortality. These results warrant evaluation of whether GSRH collection in the clinical setting improves outcomes.Ochsner Journal 01/2011; 11(3):232-40.
- [Show abstract] [Hide abstract]
ABSTRACT: Our objective was to develop a working definition of nonresponse to analgesic treatment of arthritis, focusing on the measurement of pain on the 0-100 mm pain visual analog scale (VAS). We reviewed the literature to assess the smallest detectable difference (SDD), the minimal detectable change (MDC), and the minimal clinically important difference (MCID). The SDD for improvement reported in three studies of rheumatoid arthritis was 18.6, 19.0, and 20.0. The median MDC was 25.4 for 7 studies of osteoarthritis and 5 studies of rheumatoid arthritis (calculated for a reliability coefficient of 0.85). The MCID increased with increasing baseline pain score. For baseline VAS tertiles defined by scores of 30-49, 50-65, and >65, the MCID for improvement was, respectively, 7-11 units, 19-27 units, and 29-37 units. Nonresponse can thus be defined in terms of the MDC for low baseline pain scores and in terms of the MCID for high baseline scores.05/2011; 2011:231926. DOI:10.4061/2011/231926